Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
EGCG functioned as anticarcinogen against ER-negative breast cancer cells
March 31st, 2005
EGCG has shown to be a novel anticarcinogen toward ER-negative breast cancer cells. According to recent research from the United States, "Epigallocatechin-3-gallate (EGCG) has been shown to have anticarcinogenic effects in in vitro and in vivo models, and this effect is mediated at least in part by its ability to induce apoptosis in cancer cells without affecting normal cells." "It has been recognized that estrogen receptor (ER) dependent breast cancers generally have a better prognosis and are often responsive to antiestrogen therapy; however, ER-independent breast cancers are more aggressive and unresponsive to antiestrogens," explained A.M. Roy...
Source: Women's Health Weekly (2005-03-31)
|
